S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
Log in
OTCMKTS:ATTBF

Abattis Bioceuticals Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.08
Volume2.81 million shs
Average Volume1.40 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

MarketRank

Overall MarketRank

0.38 out of 5 stars

Medical Sector

1688th out of 1,925 stocks

Biotechnology Industry

74th out of 88 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATTBF
CUSIPN/A
CIKN/A
Phone604-674-8232
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.02
0.00 (0.00 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATTBF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATTBF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abattis Bioceuticals (OTCMKTS:ATTBF) Frequently Asked Questions

How has Abattis Bioceuticals' stock price been impacted by Coronavirus?

Abattis Bioceuticals' stock was trading at $0.0077 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATTBF stock has increased by 127.3% and is now trading at $0.0175.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Abattis Bioceuticals?

Wall Street analysts have given Abattis Bioceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abattis Bioceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abattis Bioceuticals?

Abattis Bioceuticals saw a increase in short interest in December. As of December 31st, there was short interest totaling 17,700 shares, an increase of 90.3% from the December 15th total of 9,300 shares. Based on an average daily trading volume, of 3,164,800 shares, the days-to-cover ratio is currently 0.0 days.
View Abattis Bioceuticals' Short Interest
.

Who are some of Abattis Bioceuticals' key competitors?

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the following people:
  • Mr. Robert J. Abenante, Pres, CEO & Director (Age 37)
  • Mr. Douglas J. Sorocco LLB, Advisor (Age 49)
  • Mr. Guy P. Dancosse, Advisor (Age 76)
  • Mr. Francesco Paolini, CFO & Director
  • Mr. Patrick Mitchell, COO & Director
  • Mr. Shawn Balaghi, Head of Corp. Devel.
  • Mr. Clayton Chessa, Head of Operations
  • Mr. Jim Carter, Head of Mergers and Acquisitions Advisory
  • Mr. Christopher P. Cherry C.A., C.P.A., CPA, CA, CGA, Corp. Comptroller (Age 41)
  • Ms. Nicole Breitinger, Corp. Sec.

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the OTCMKTS under the ticker symbol "ATTBF."

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abattis Bioceuticals' stock price today?

One share of ATTBF stock can currently be purchased for approximately $0.02.

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is www.abattis.com.

How can I contact Abattis Bioceuticals?

The company can be reached via phone at 604-674-8232.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.